Drug Profile
Research programme: anticancer vaccines - PHAXIAM Therapeutics
Alternative Names: ERY-VAX; Gr-VaxLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator ERYtech Pharma
- Developer PHAXIAM Therapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)